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eTable1: Features of the databases included in the study 
Database Country Type of database and setting  
Study 
Period 
Diagnosis coding 
Prescription 
coding 
Source 
population 
AARHUS Denmark 
NHS-linkedregional database(Northern and Central 
Region of Jutland) – community and in/out-patient 
hospital setting  
2000-2010 ICD-10 ATC 1,559,718 
ERD Italy 
NHS-linked regional database (Emiglia Romagna 
region) – community setting 
2005-2010 ICD-9 CM ATC 6,079,798 
HSD-CSD-LPD Italy 
General practicenationwide database – community 
setting  
2000-2010 
ICD-9 CM and free 
text 
ATC 1,240,561 
GePaRD Germany 
General practicenationwide database – community and 
hospital setting 
2005-2009 ICD-10 GM ATC 7,285,935 
IPCI Netherlands 
General practicenationwide database – community 
setting  
1998-2010 ICPC and freetext ATC 1,016,632 
PHARMO Netherlands Nationwide record linkagesystem – community setting 1999-2009 ICD-9 CM ATC 4,625,868 
THIN UK 
Nationwide general practicedatabase – community 
setting 
1997-2010 READand free text BNF/ Multilex 6,951,894 
Abbreviations: ATC- Anatomic Therapeutic Chemical drug classification; BNF- British National Formulary codes; ERD- Emilia-Romagna Database; GEPARD-  German 
PharmacoepidemiologicalResearch Database;  HSD-CSD-LPD- Health Search Database-Cegedim-Strategic Data-Longitudinal Patient Database; ICD-9 CM- International classification of Diseases, 9th 
edition, clinical modification; ICD-10- International classification of Diseases, 10th edition; ICD-10 GM- International classification of Diseases, 10th edition, German modification; ICPC- International 
Classification of Primary Care codes; IPCI- Integrated Primary Care Information; NHS- National Health Service; THIN- The Health Improvement Network; UK- United Kingdom 
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eFigure1:Coding algorithm for ventricular arrhythmia identification 
 
 
 
 
 
 
 
 
Legend: Ventricular Arrhythmia (VA) includes both ventricular tachycardia (VT) and fibrillation (VF). VT is a sequence of three or more beats in a row, with wide QRS complex (QRS ≥120 ms) at a 
ventricular rate exceeding 100 beats/min. If the rhythm lasts more than 30 seconds or requires termination earlier due to hemodynamic instability, it is known as a sustained ventricular tachycardia. If the 
fast rhythm self-terminates within 30 seconds, it is considered a non-sustained ventricular tachycardia. VT can evolve to VF that is a rapid, chaotic, non-repetitive waveform usually preceded by rapid VT 
and in which there is uncoordinated contraction of the cardiac muscle of the ventricles. VF is clinically associated with loss of effective blood circulation and, if not immediately treated, leads to death.For 
this analysis, VA was considered as two separated outcomes: non-fatal and fatal VA with the latter defined as death within 48 hours from the event of interest. In our study, CA was analyzed as part of 
VA as well as separate outcome. All cases of CA with successful resuscitation were considered as non-fatal VA, while CAs in which the patient died within 48 hours from the beginning of symptoms were 
considered as fatal VA. Abbreviations: CA- cardiac arrhythmia; IV- intravenous; VA- ventricular arrhythmia; VF- ventricular fibrillation; VT- ventricular tachycardia  
 
 
 
 
 
Diagnosisof VA AND (Procedure done to treat/diagnose VA OR Prodromic symptom) 
Diagnosis of VF AND (Procedure done to treat/diagnose VA OR Prodromic symptom) 
Diagnosis of resuscitated CA AND (Procedure done to treat/diagnose VA OR Prodromic symptom) 
 
Diagnosis of fatal CA,VT, VF 
For GP databases:Diagnosis of VA, VT, VF AND Diagnosis made by specialist 
 
OR 
OR 
OR 
OR 
Diagnosis of VT AND (Procedure done to treat/diagnose VA OR Prodromic symptom) 
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eTable2: Unified Medical Language-driven identification of terminology specific codes for ventricular arrhythmia and cardiac 
arrest 
UMLS concept Preferred term of concept ICD-9 ICD-10 ICD-10GM ICPC RCD v2 
Ventricular arrhythmia 
C0085612 Ventricular arrhythmia 
    
328..00, 328Z.00 
C0042514 Tachycardia, Ventricular 427.1 I47.2 I47.2 K79005 G571.00 
C0030591 Paroxysmal ventricular tachycardia 427.1 
   
G571.11 
C0152173 Ventricular Flutter 427.42 
  K80014, K84011 
G574100 
C0155710 Ventricular fibrillation and flutter 427.4 I49.0 I49.0 
 
G574.00, G574z00 
C0349069 Re-entry ventricular arrhythmia 
 
I47.0 I47.0 
 
G57Ya00 
C0042510 Ventricular Fibrillation 427.41 
  
K84020, K80011 
G574000 
G574011 
C0494598 Other cardiac dysrhythmias 427.9 I49.9 
  
G57..00 
Cardiac arrest 
C0018790 Cardiac Arrest 427.5 I46, I46.9 
I46 
I46.9 K84005 
G575.00, G575z00 
C0340514 Cardiac arrest with successful resuscitation 
 
I46.0 I46.0 
 
G575000 
C0340513 Cardiac arrest as a complication of care 
    
SP11000 
C0600228 Cardiopulmonary Arrest 427.5 
   
G575.11 
C1260909 Cardiorespiratory failure as a complication of care 
    
SP11200 
C0397419 Direct current defibrillation 
    
7L1H.00, 7L1H.11, 
7L1H.12, 7L1H.13 
C0436588 O/E - collapse -cardiac arrest 
    
2241.00 
Abbreviations: ICD-9- International Classification of Disease, 9th version; ICD-10- International Classification of Disease, 10th version; ICD-10 GM- International Classification of Disease, 10th version, 
German modification; ICPC- International Classification of Primary Care code; RDC v2.- Read code version 2; UMLS- Unified Medical Language System
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eTable3: Coding algorithms for covariates included in the study 
Well-known risk factors for VA 
Covariate name Search criteria Time frame Notes 
Atrial fibrillation/flutter Dx 
Anytime prior 
to ID 
 
Cardiomyopathies Dx 
Anytime prior 
to ID 
It includes cardiomyopathies and 
channelopathies 
Cerebrovascular events Dx 
Anytime prior 
to ID 
 
Coronary heart disease Dx or RX 
Anytime prior 
to ID 
ATC: C01D* as proxy of disease 
Heart failure Dx 
Anytime prior 
to ID 
 
Hypertension 
Dx or blood 
pressure 
measurements or 
Rx 
Anytime prior 
to ID 
ATC: C09A-D*, C07*, C08*, 
C02A-K*, C02N* as proxy of 
disease. Two systolic blood 
pressure measurements with 
exceeding 140 were considered 
to denote hypertension. 
Peripheral arterial disease Dx 
Anytime prior 
to ID 
 
Antiarrhythmia drug use Rx 
Anytime prior 
to ID 
See Table S3 for ATC codes 
Electrolytic imbalance 
Dx or laboratory 
values 
Anytime prior 
to ID 
It includes hypocalcemia, 
hypokalemia and 
hypomagnesemia 
Use of QT prolonging drugs Rx 
90 days prior 
to ID 
Drugs with established 
TdPliability, based on 
CredibleMeds list** 
See Table S4 for ATC codes 
Concomitant use of QT 
prolonging drugs other than 
drugs under study 
Rx 
90 days prior 
to ID 
See Table S5 for ATC codes 
Concomitant use of medications 
inducing hypokalemia 
Rx 
90 days prior 
to ID 
See Table S6 for ATC codes 
Potential risk factors for VA 
Acute and Chronic Renal Failure Dx 
Anytime prior 
to ID 
 
Alcohol abuse Dx 
Anytime prior 
to ID 
 
Chronic liver disease Dx 
Anytime prior 
to ID 
 
Chronic respiratory disease DX or Rx 
Anytime prior 
to ID 
ATC: R03 as proxy of disease 
Conduction disorders Dx 
Anytime prior 
to ID 
 
Congenital heart disease Dx 
Anytime prior 
to ID 
 
Diabetes mellitus Dx or Rx 
Anytime prior 
to ID 
ATC: A10* as proxy of disease 
Hyperthyroidism Dx or Rx 
Anytime prior 
to ID 
ATC: H03B* as proxy of disease 
Hypothyroidism Dx or Rx 
Anytime prior 
to ID 
ATC: H03A*, H03C* as proxy of 
disease 
Lipid metabolism disorders Dx or Rx 
Anytime prior 
to ID 
ATC: C10* as proxy of disease 
Obesity Dx or BMI≥ 30 or Rx 
Anytime prior 
to ID 
ATC: A08* as proxy of disease 
Other cardiac arrhythmias* Dx Anytime prior  
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to ID 
Cardiac valve disorders Dx 
Anytime prior 
to ID 
 
Abbreviations: Dx- diagnosis; ID- index date; Rx- prescription; VA: ventricular arrhythmia  
* Except for atrial fibrillation/flutter, conduction disorders, QT prolongation, ventricular arrhythmia and sudden cardiac death. ** 
CredibleMeds. CredibleMeds webpage. (Accessed January 15, 2014 at https://crediblemeds.org/) 
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eTable4: Anti-arrhythmia drugs 
Anti-arrhythmic drugs, class I and III ATC code 
Quinidine C01BA01 
Procainamide C01BA02 
Disopyramide C01BA03 
Sparteine C01BA04 
Ajmaline C01BA05 
Prajmaline C01BA08 
Lorajmine C01BA12 
Quinidine, combinations excl. psycholeptics C01BA51 
Quinidine, combinations with psycholeptics C01BA71 
Lidocaine C01BB01 
Mexiletine C01BB02 
Tocainide C01BB03 
Aprindine C01BB04 
Propafenone C01BC03 
Flecainide C01BC04 
Lorcainide C01BC07 
Encainide C01BC08 
Amiodarone C01BD01 
Bretyliumtosilate C01BD02 
Bunaftine C01BD03 
Dofetilide C01BD04 
Ibutilide C01BD05 
Tedisamil C01BD06 
Dronedarone C01BD07 
Moracizine C01BG01 
Cibenzoline C01BG07 
Vernakalant C01BG11 
Abbreviations: ATC- Anatomical Therapeutic Chemical classification  
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eTable5:Drugs with established torsadogenic liability 
Drug ATC code 
Amiodarone C01BD01 
Arsenic trioxide L01XX27 
Astemizole R06AX11 
Bepridil C08EA02 
Chloroquine P01BA01 
Cisapride A03FA02 
Citalopram N06AB04 
Clarithromycin J01FA09 
Disopyramide C01BA03 
Dofetilide C01BD04 
Domperidone A03FA03 
Erythromycin J01FA01 
Flecainide C01BC04 
Halofantrine P01BX01 
Ibutilide C01BD05 
Levomethadyl N07BC03 
Methadone N07BC02 
Moxifloxacin J01MA14 
Pentamidine P01CX01 
Probucol C10AX02 
Procainamide C01BA02 
Quinidine C01BA01 
Sotalol C07AA07 
Sparfloxacin J01MA09 
Terphenadine R06AX12 
Vandetanib L01XE12 
Abbreviations: ATC- Anatomical Therapeutic Chemical classification 
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eTable6: Drugs known to induce hypokalemia  
Drug class Drug name ATC code 
Thiazides 
Bendroflumethiazide C03AA01 
Hydroflumethiazide C03AA02 
Hydrochlorothiazide C03AA03 
Chlorothiazide C03AA04 
Polythiazide C03AA05 
Trichlormethiazide C03AA06 
Cyclopenthiazide C03AA07 
Methyclothiazide C03AA08 
Cyclothiazide C03AA09 
Mebutizide C03AA13 
Bendroflumethiazide and potassium C03AB01 
Hydroflumethiazide and potassium C03AB02 
Hydrochlorothiazide and potassium C03AB03 
Chlorothiazide and potassium C03AB04 
Polythiazide and potassium C03AB05 
Trichlormethiazide and potassium C03AB06 
Cyclopenthiazide and potassium C03AB07 
Methyclothiazide and potassium C03AB08 
Cyclothiazide and potassium C03AB09 
Chlorothiazide, combinations C03AH01 
Hydroflumethiazide, combinations C03AH02 
Hydrochlorothiazide, combinations C03AX01 
High-Ceiling Diuretics 
Furosemide C03CA01 
Bumetanide C03CA02 
Piretanide C03CA03 
Torasemide C03CA04 
Furosemide and potassium C03CB01 
Bumetanide and potassium C03CB02 
Ethacrynic acid C03CC01 
Muzolimine C03CD01 
Etozolin C03CX01 
Corticosteroids for systemic 
use, plain 
Aldosterone H02AA01 
Fludrocortisones H02AA02 
Prednisone H02AB07 
Selective beta-2-
adrenoreceptor agonists 
 
Salbutamol R03AC02 
Terbutaline R03AC03 
Fenoterol R03AC04 
Rimiterol R03AC05 
Hexoprenaline R03AC06 
Isoetarine R03AC07 
Pirbuterol R03AC08 
Tretoquinol R03AC09 
Carbuterol R03AC10 
Tulobuterol R03AC11 
Salmeterol R03AC12 
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Formoterol R03AC13 
Clenbuterol R03AC14 
Reproterol R03AC15 
Procaterol R03AC16 
Bitolterol R03AC17 
Indacaterol R03AC18 
Catecholamines 
Epinephrine C01CA24 
Norepinephrine C01CA03 
Dopamine C01CA04 
Abbreviations: ATC- Anatomical Therapeutic Chemical classification of drugs 
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eFigure2: Patient selection from the seven databases 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations:ERD - Emilia-Romagna Database; GEPARD-German Pharmacoepidemiological Research Database; HSD - Health 
Search Database-Cegedim-Strategic Data-Longitudinal Patient Database; IPCI- Integrated Primary Care Information; THIN - The Health 
Improvement Network 
 
Source population 
Aarhus: 1,559,718 
ERD: 6,079,798 
GEPARD: 7,285,935 
HSD: 1,240,561   Total:28,760,406 
IPCI: 1,016,632 
PHARMO: 4,625,868  
THIN: 6,951,894 
 
Cases among incident antibiotic users 
Aarhus: 2,480 
ERD: 1,046 
GEPARD: 1,992 
HSD: 952                                Total: 12,947 
IPCI: 131 
PHARMO: 1,998 
THIN: 4,348 
 
Incident antibiotic users free of cancer before cohort 
entry and during follow-up 
Aarhus: 631,877 
ERD: 3,973,761 
GEPARD: 3,507,669 
HSD: 714,978                              Total:14,040,688 
IPCI: 301,526 
PHARMO: 1,597,731 
THIN: 3,313,146 
 
Cases among incident antibiotic users 
currently exposed to azithromycin/amoxicillin/ 
other antibiotics  
 
AzithromycinAmoxicillin   Any other antibiotic  
            30                   165                 1,026 
Controls among incident antibiotic users 
Aarhus 240,973 
ERD: 104,143 
GEPARD: 184,173 
HSD: 84,419                   Total: 1,240,783 
IPCI: 9,306 
PHARMO: 197,313 
THIN: 420,456 
 
Controls among incident antibiotic users 
currently exposed to azithromycin/amoxicillin/ 
other antibiotics  
 
AzithromycinAmoxicillin   Any other antibiotic  
        1,344                  370                 52,543 
